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ABOUT THE JOURNAL 
SCOPE 
Clinical and Translational Science (CTS), an 
official journal of the American Society for Clinical 
Pharmacology and Therapeutics, highlights original 
translational medicine research that helps bridge 
laboratory discoveries with the diagnosis and treatment 
of human disease. Translational medicine is a multi-
faceted discipline with a focus on translational 
therapeutics. In a broad sense, translational medicine 
bridges across the discovery, development, regulation, 
and utilization spectrum. Research may appear as Full 
Articles, Brief Reports, Commentaries, Phase Forwards 
(clinical trials), Reviews, or Tutorials. CTS also includes 
invited didactic content that covers the connections 
between clinical pharmacology and translational 
medicine. These additional features provide context 
for research articles and facilitate understanding for 
a wide array of individuals interested in clinical and 
translational science. CTS welcomes high quality, 
scientifically sound, original manuscripts focused 
on clinical pharmacology and translational science, 
including animal, in vitro, in silico, and clinical studies 
supporting the breadth of drug discovery, development, 
regulation and clinical use of both traditional drugs and 
innovative modalities.
Topics of interest include:
• Translational medicine, including studies focused on 
Interrogation/evaluation of mechanism-of-action, 
human physiology, and interruption of disease 
pathophysiology
• Hypothesis generating non-clinical and clinical 
studies, including small clinical trials 
• Clinical pharmacology studies with a focus on 
translational research in discovery, development, 
regulation and use of pharmacologic agents to 
improve clinical outcome, and inform optimal use of 
therapeutics in patients
• Evaluation of various biomarkers as well as 
assessing the linkage between biomarker response 
and clinical endpoints in patients, including studies 
that identify or support biomarkers that can be used 
at any stage of drug development
• Studies of response to a therapeutic intervention in 
a particular disease that may translate to a response 
in another disease, as well as translation of safety 
signals across species and/or patient populations
• The science and practice of translational medicine, 
including topics such as models of human disease 
and their therapeutic implications as well as 
practical aspects like improvements to study design 
or conduct and translational medicine methods.  
• Studies that guide Phase 2 dose selection
• Studies that demonstrate effective translation 
between basic and clinical science
• Precision medicine
• Genomic medicine, including 
pharmacogenomics, next generation sequencing, 
pharmacometabolomics, and functional genomics
• Electronic and mobile health applications as well as  
wearables
• Regulatory and public health policy implications of 
translational studies
• Quantitative and systems pharmacology, PK/PD 
model-based and mechanistic understanding of 
disease biology and pharmacology, as these relate 
to translational medicine
CTS is an official journal of the American Society for 
Clinical Pharmacology and Therapeutics (ASCPT).
ISSN 2163-8306
URL http://cts.msubmit.net
ABSTRACTING
This journal is covered by: Academic Search (EBSCO 
Publishing), Academic Search Alumni Edition (EBSCO 
Publishing), Biological Abstracts (Thomson Reuters), 
BIOSIS Previews (Thomson Reuters), Biotechnology & 
Bioengineering Abstracts (ProQuest), CSA Biological 
Sciences Database (ProQuest), Embase (Elsevier), 
MEDLINE/PubMed (NLM), Science Citation Index 
Expanded (Thomson Reuters), SCOPUS (Elsevier), and 
Web of Science (Thomson Reuters).
EDITORIAL PROCESS
Criteria for Publication 
The principal criteria for publication of papers in CTS are 
that they:
• Report original scientific research (the main results 
and conclusions must not have been published or 
submitted elsewhere)
• Are of outstanding scientific importance
• Reach a conclusion of interest to an interdisciplinary 
readership
Selection Process of Submitted Papers
Upon submission, the manuscript is assigned to an 
Associate Editor covering the subject area, who makes 
the initial decision on whether to send it out for peer-
review. The journal receives many more high-quality 
submissions than it can publish and the Associate 
Editors strive to identify maximally impactful papers. 
Papers not chosen for peer-review are quickly returned 
to the authors to minimize unproductive delays and 
allow sufficient time to prepare the manuscript for 
submission to another journal.
If selected for peer review, referees are chosen by the 
Associate Editor based upon subject expertise and 
ability to evaluate the paper fully and fairly, and in a 
timely manner. The ideal referee report indicates who 
will be interested in the new results and why, and will 
be used by the Associate Editor to help determine 
the impactfulness of publication in CTS. If a paper is 
selected for further consideration, authors are required 
to address the comments of the referees in a revised 
version of the paper.
The Associate Editor assigned to the paper is 
responsible for making a decision recommendation in 
light of the referees’ reports. All recommendations are 
then considered by the Editor-in-Chief, who determines 
the final disposition for all papers.
OPEN ACCESS PUBLICATION
All articles selected for acceptance in CTS will 
be published open access. Articles will be made 
freely available immediately upon publication. For 
accepted papers, the author identified as the formal 
corresponding author for the paper will receive an email 
prompting them to login into Author Services; where via 
the Wiley Author Licensing Service (WALS) they will be 
able to complete the license agreement on behalf of all 
authors on the paper.
The following license agreements are available:
Creative Commons Attribution Non-Commercial (CC-BY-
NC) license
Creative Commons Attribution-Non-Commercial-
NoDerivs (CC-BY-NC-ND) license.
From April 1, 2013, RCUK or Wellcome trust funded 
authors will be directed to sign the open access 
agreement under the terms of the Creative Commons 
Attribution (CC-BY) license in order to be funder 
compliant.
For more information on the terms and conditions 
of these licenses, please visit: http://www.
wileyopenaccess.com/details/content/12f25db4c87/
Copyright--License.html
Authors are required to pay an article processing fee 
per accepted article. The article processing charge is 
$3,000/£2,000/€2,500 (plus VAT where applicable) 
for papers published under the Creative Commons 
Attribution Non-Commercial (CC-BY-NC) and the 
Creative Commons Attribution-Noncommercial-No 
Derivative Works 3.0 Unported License (CC BY-NC-
ND). ASCPT members and dual ASCPT-ISoP members 
will receive a reduced Article Processing Charge. The 
Article Processing Charge can be paid via credit card or 
by requesting that an invoice be issued. By paying this 
Article Processing Charge, authors are permitted to post 
the final, published PDF of their article on a website, 
institutional repository, or other free public server 
immediately upon publication. 
PREPARATION OF MANUSCRIPTS 
CONTENT TYPES
Author Submissions (1) Article, (2) Review,  
(3) Phase Forward, (4) Commentary, (5) Book Review, 
(6) Letter to the Editor, (7) Tutorial, (8) Brief Report
Submissions that do not adhere to the guidelines 
provided in this document will be returned to the 
author prior to consideration. Material that cannot 
fit within the allowed limit may be submitted as 
supplementary information.
(1) Article
Word Limit: 4,000 words excluding abstract, references, 
tables, and figures
Abstract: 150 words maximum
References: 50 maximum
Figures/Tables: 7 maximum
Substantial novel research
(2) Review
Word Limit: 4,000-8,000 words excluding introduction, 
references, tables, and figures
Abstract: no abstract for this article type; should include 
a 75-word Introduction
References: 75-100 maximum
Figures/Tables: 8 maximum
High-quality, timely reviews covering important topics in 
the entire field of translational medicine
(3) Phase Forward
Word Limit: 5,000 words excluding abstract, references,
 tables, and figures
Abstract: 150 words maximum
References: 60 maximum
Figures/Tables: 8 maximum
Manuscripts developed from well-conducted, well 
reported, and relevant clinical trials with a particular 
focus on first-in-human, first-in-patient, and proof-
of-concept.
(4) Commentary
Word Limit: 1,600 words excluding introduction, 
references, tables, and figures
Abstract: no abstract for this article type; should include 
a 75-word Introduction
References: 10 maximum
Figures/Tables: 2 maximum
Typically highlights findings of a paper in the same issue, 
presented in a wider scientific and clinical context
(5) Book Review
Word Limit: 700 words
Abstract: no abstract for this article type
References: no references for this article type
Figures/Tables: Cover image will be secured prior to 
publication by the Editorial Office
(6) Letter to the Editor
Word Limit: 400 words excluding references, tables, and 
figures
Abstract: no abstract for this article type
References: 5 maximum
Figures/Tables: 1 maximum
Letters must be submitted within 6 months of 
publication of the subject article. A Letter to the 
Editor must reference the original source, and a 
Response to Letter must reference the Letter to the 
Editor in the first few paragraphs. Letters to the 
Editor can use an arbitrary title, but a Response 
must cite the title of the Letter: e.g., Response to 
[title of Letter
(7) Tutorial
Word Limit: 4,000-8,000 excluding introduction, 
references, tables, and figures
Abstract: no abstract for this article type; should include 
a 75-word introduction
References: 75-100 maximum
Figures/Tables: 8 maximum
Educational article providing practical tutorial on tools, 
methodologies and approaches in translational 
medicine.
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(8) Brief Report
Word Limit: 2,000 excluding abstract, references, tables, 
and figures. Results and Discussion sections may be 
combined.
Abstract: 150 words maximum
References: 25 maximum
Figures/Tables: 2 maximum
Brief Reports are intended as short and complete 
reports of novel research findings of high 
importance to the field. Reports of preliminary 
experiments are unacceptable. Brief reports 
should be especially significant and timely and 
reach a clear conclusion.
FORMAT OF MANUSCRIPTS
General format Manuscripts must be typed in English 
and be in a single column, double-spaced format. All 
manuscript pages must be numbered. Manuscript text 
files must be in MS Word or LaTeX format.
Title page This should include (a) the complete 
manuscript title; (b) all authors’ names and affiliations; 
and (c) the name and address for correspondence, fax 
number, telephone number, and e-mail address. The 
title page should also include the number of figures and 
tables and the key words.
Title Manuscript titles should be no more than 150 
characters and spaces. Running titles should be no more 
than 50 characters and spaces.
Text Articles should consist of the following ordered 
sections: 
Title Page
Abstract
Introduction
Methods (must contain IRB or IACUC approval: see 
Informed Consent and Ethics below)
Results
Discussion
Study Highlights
Acknowledgements
Conflict of Interest/Disclosure
Author Contributions
References
Figure Legends
Originality A submitted manuscript must be an 
original contribution not previously published (except 
as an abstract), must not be under consideration 
for publication elsewhere, and, if accepted, must 
not be reproduced elsewhere without the consent 
of the American Society for Clinical Pharmacology 
and Therapeutics (ASCPT). Although the editors, 
editorial board, and referees make every effort to 
ensure the validity of published manuscripts, the final 
responsibility rests with the authors, not with Clinical 
and Translational Science, its editors, ASCPT, or Wiley.
Conflict of Interest CTS subscribes to the Uniform 
Requirements for Manuscripts Submitted to Biomedical 
Journals. These principles require that participants 
in the peer review and publication process disclose 
all relationships that could be viewed as presenting 
a potential conflict of interest. Disclosures must 
include employment, consultancies, honoraria, stock 
ownership, stock options, expert testimony, grants 
received and pending, patents received and pending, 
royalties, and in-kind contributions. Editors may publish 
disclosed information if they believe readers will find it 
important in judging the manuscript. Institutional and 
personal conflicts of interest must also be declared.
Informed Consent and Ethics CTS adheres to the 
Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals established by the International 
Committee of Medical Journal Editors. A full description 
of recommendations can be found at http://www.icmje.
org. Research projects involving human subjects require 
review and approval by an Institutional Review Board 
(IRB). When reporting experiments on human subjects, 
indicate whether the procedures were in accordance 
with the ethical standards of the responsible committee 
on human experimentation or with the Helsinki 
Declaration of 1975 (as revised in 1983). IRB or IACUC 
approval must be cited in the Methods section of the 
text. If there has been no IRB review of the study, please 
indicate so in the cover letter. In such situations, the 
manuscript will be reviewed to determine if IRB review 
should have been conducted. The result of this review 
may determine whether or not the manuscript will be 
considered for publication.
Statement of Human and Animal Rights When 
reporting experiments on human subjects, authors 
should indicate whether the procedures followed 
were in accordance with the ethical standards of the 
responsible committee on human experimentation 
(institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2008 (5). If doubt 
exists whether the research was conducted in 
accordance with the Helsinki Declaration, the authors 
must explain the rationale for their approach and 
demonstrate that the institutional review body explicitly 
approved the doubtful aspects of the study. When 
reporting experiments on animals, authors should 
indicate whether the institutional and national guide for 
the care and use of laboratory animals was followed.
Clinical Trials Registry Registration in a public trials 
registry is required for publication in CTS. A clinical trial 
is defined as any research project that prospectively 
assigns human subjects to intervention or comparison 
groups to study the cause-and-effect relationship 
between a medical intervention and a health outcome. 
Studies designed for other purposes, including exploring 
pharmacokinetics or safety and tolerability (e.g., phase 
1 trials) are exempt. Registration must be with a registry 
that meets the following criteria: (1) accessible to 
the public at no charge; (2) searchable by electronic 
methods; (3) open to all prospective registrants free 
of charge or at minimal cost; (4) validates registered 
information; (5) identifies trials with a unique number; 
and (6) includes information on the investigator(s), 
research question or hypothesis, methodology, 
intervention and comparisons, eligibility criteria, 
primary and secondary outcomes measured, date of 
registration, anticipated or actual start date, anticipated 
or actual date of last follow-up, target number of 
subjects, status (anticipated, ongoing or closed), and 
funding source(s). Examples of registries that meet 
these criteria include (1) The registry sponsored by 
the United States National Library of Medicine (http://
www.clinicaltrials.gov); (2) The International Standard 
Randomised Controlled Trial Number Registry (http://
www.controlled-trials.com); (3) The Cochrane Renal 
Group Registry (http://www.cochrane-renal.org/
trialsubmissionform.php); (4) The National (United 
Kingdom) Research Register (http://www.update-
software.com/national/); and (5) European Clinical Trials 
Database (http://eudract.emea.eu.int/).
Abbreviations Abbreviations should be defined at the 
first mention in the text and in each table and figure. 
Write out the full term for each abbreviation at its first 
use unless it is a standard unit of measure. For a list of 
standard abbreviations, please consult the CSE Manual 
for Authors, Editors, and Publishers (available from the 
Council of Science Editors, 12100 Sunset Hills Road, 
Suite 130, Reston, VA 20190) or other standard sources. 
Style The American Medical Association Manual of 
Style (9th edition), Stedman’s Medical Dictionary (27th 
edition) and Merriam-Webster’s Collegiate Dictionary 
(10th edition) should be used as standard references. 
Refer to drugs and therapeutic agents by their accepted 
generic or chemical name, and do not abbreviate them 
(a proprietary name may be given only with the first use 
of the generic name). Code names should be used only 
when a generic name is not yet available (the chemical 
name and a figure giving the chemical structure of 
the drug is required). Copyright or trade names of 
drugs should be capitalized and placed in parentheses 
after the name of the drug. Names and locations (city 
and state in United States; city and country outside 
United States) of manufacturers of drugs, supplies, 
or equipment cited in a manuscript are required to 
comply with trademark law and should be provided in 
parentheses.
Language Editing Authors who require editing for 
language are encouraged to consult language editing 
services prior to submission. 
STUDY HIGHLIGHTS
Original research articles should include a Study 
Highlights section after the Discusssion section in the 
manuscript text. The highlights section should include 
and answer each of the questions below. The entire 
section, not including the questions, should be under 
150 words.
•What is the current knowledge on the topic?
•What question did this study address?
•What this study adds to our knowledge
• How this might change clinical pharmacology or 
translational science
AUTHOR RESPONSIBILITY 
Upon submission, the corresponding author must 
confirm full access to all data in the study and final 
responsibility. 
AUTHOR CONTRIBUTIONS
A list of each authors’ contributions should be provided 
in the manuscript text. The standard contributions 
include: Wrote Manuscript, Designed Research, 
Performed Research, Analyzed Data, and Contributed 
New Reagents/Analytical Tools. 
ACKNOWLEDGMENTS 
This should include sources of support, including federal 
and industry support. All authors who have contributed 
to the manuscript must be acknowledged. Medical 
writers, proofreaders, and editors should not be 
designated as full authors, but acknowledged here.
DISCLOSURE 
At the time of submission, each author must disclose 
and describe any involvement, financial or otherwise, 
that might potentially bias his or her work. Disclosures 
must be included in the text of the manuscript and the 
online submission form.
REFERENCES 
The reference list should contain the references in the 
order in which they are cited in the text (Vancouver 
style). Citations included in tables/figures count toward 
the maximum references allowed for the article type 
and must be included in the reference list.  Tables 
created solely of references are not permitted. Only 
published works, as well as manuscripts in press, 
should be included in the reference list; articles that 
are submitted or in preparation should be referred 
to as “unpublished data” in the text. For publications 
in the reference list, all authors should be included 
unless there are more than 6, in which case only the 
first author should be listed followed by ‘et al.’ Titles 
of cited articles are required for all article types. For 
book citations, the publisher and city of publication 
are required; include the country (and state for US) for 
lesser-known cities or where any ambiguity is possible.
Please note the following examples:
Journal articles:
Kashuba, A.D. et al. Effect of fluvoxamine therapy on the 
activities of CYP1A2, CYP2D6, and CYP3A as determined 
by phenotyping. Clin. Pharmacol. Ther. 64, 257–268 
(1998).
Books:
Eisen, H.N. Immunology: An Introduction to Molecular 
and Cellular Principles of the Immune Response 5th edn. 
(Harper & Row, New York, 1974). 
Articles in books: 
Weinstein, L. & Schwartz, M.N. Pathogenic properties 
of invading microorganisms. In Pathologic Physiology: 
Mechanisms of Disease (eds. Sodeman, W.A., Jr. & 
Sodeman, W.A.) 457–473 (W.B. Saunders, Philadelphia, 
1974).
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GUIDELINES FOR FIGURES AND ARTWORK
Detailed guidelines for submitting figures and artwork 
can be found at: http://authorservices.wiley.com/
prep_illust.asp. Using the guidelines, please submit 
production quality artwork at submission. Accepted 
figure files include PDF, TIFF, and EPS in PC format, 
preferably from Photoshop or Illustrator software. We 
can also accept Freehand 8, Canvas and CorelDraw 
(version 8 and above), but these files must be converted 
to postscript (EPS) format. For any figures submitted in 
Photoshop or TIFF format, we require layered files to 
be sent whereby all text, arrows or additional attributes 
are placed in individual layers within the file. 
For single images:
Width 500 pixels (authors should select “constrain 
proportions,” or equivalent instructions, to allow 
the application to set the correct proportions 
automatically)
Resolution 125 dpi (dots per inch)
Format TIFF for photographs, EPS for line drawings 
or charts
File naming Please save image with .tiff or .eps 
extension to ensure it can be read by all platforms 
and graphics packages
For multi-part images:
Width 900 pixels (authors should select “constrain 
proportions,” or equivalent instructions, to allow 
the application to set the correct proportions 
automatically)
Resolution 125 dpi (dots per inch)
Format TIFF for photographs, EPS for line drawings 
or charts
File naming Please save image with .tiff or .eps 
extension to ensure it can be read by all platforms 
and graphics packages
FIGURES 
Figures should be numbered consecutively in the order 
of first citation in the text. If a table, figure or any other 
previously published material is included, the authors 
must obtain written permission to reproduce the 
material from the copyright owner and submit it with 
the manuscript. The original source should be cited. 
Figures and tables must be uploaded separately from 
the manuscript text. Each figure must be provided as an 
individual file. Composite figures should be submitted 
preassembled. Authors are encouraged to use color in 
their figures.
FIGURE LEGENDS 
Legends should be brief and specific and should appear  
after the Reference section in the manuscript text.
TABLES 
Accepted file types include MS Word. If you submit a 
LaTeX file, please provide a PDF copy as reference for 
the editorial staff. This PDF copy can be uploaded as 
a supplementary information file. Tables should be 
numbered consecutively in the order of first citation 
in the text. Supply a brief title for each table but 
place explanatory matter in the footnotes (not in the 
heading). Do not use internal horizontal and vertical 
lines. Tables and figures must be uploaded separately 
from the manuscript text. Please do not include 
multipart tables (such as Table 1a and 1b). Tables should 
be editable and not embedded images or excel files.
JOURNAL STYLE 
Papers should be prepared as follows:
1. See the artwork guidelines above
2. Do not make rules thinner than 1 pt (0.36mm)
3. Use a coarse hatching pattern rather than shading for 
tints in graphs
4. Color should be distinct when used as an identifying 
tool
5. Commas should be used to separate thousands
6. At first mention of a manufacturer, the town (state if 
USA) and country should be provided
FILE FORMATS & REQUIREMENTS 
Authors are required to submit final, publication-ready 
files at the revision stage, along with a version tracking 
all changes to the paper. Use the Track Changes mode 
in MS Word or indicate the revised text with bold, 
highlighted, or colored type. Authors should submit 
a point-by-point response to each referees’ set of 
comments.
SUPPLEMENTARY INFORMATION 
Supplementary information is peer-reviewed material 
directly relevant to the conclusion of an article that 
cannot be included in the printed version owing to 
space or format constraints. It is posted on the journal’s 
website and linked to the article online; it may include 
data files, graphics, movies, or extensive tables. The 
printed article must be complete and self-explanatory 
without the supplementary information.
Supplying Supplementary Information Files Authors 
should ensure that supplementary information is 
supplied in its FINAL format at submission, as it is 
not copy edited and will appear online exactly as 
submitted. It cannot be altered, nor new supplementary 
information added, after the paper has been accepted 
for publication. Please supply the supplementary 
information via the electronic manuscript submission 
system in an acceptable file format. Each supplementary 
figure must be provided as an individual high-
resolution PDF, TIFF, or EPS file. Each supplementary 
table must be provided as an individual MS Word or 
Excel. Supplementary text must be provided in MS 
Word or Excel format. The number of supplementary 
information files should be limited to eight, and the 
total file size should not exceed 8 MB. Individual files 
should not exceed 1 MB. 
Accepted File Formats File sizes must be as small as 
possible to expedite downloading. Images should not 
exceed 640 x 480 pixels. Movie files can be in Quick 
Time (.mov), or MPEG (.mpg) format. For movies, 
we recommend 480 x 360 pixels as the maximum 
frame size and a frame rate of 15 frames per second. 
If applicable to the presentation of the information, 
use a 256-color palette. Please consider the use 
of lower specification for all of these points if the 
supplementary information can still be represented 
clearly. Our recommended maximum data rate is 150 
KB/s. Questions about the submission or preparation of 
supplementary information should be directed to the 
editorial office.
EDITORIAL POLICIES 
PLAGIARISM 
Plagiarism is when an author attempts to represent 
someone else’s work as his or her own. Duplicate 
publication, sometimes called self-plagiarism, occurs 
when an author reuses substantial parts of his or her 
own published work without providing the appropriate 
references. This can range from getting an identical 
paper published in multiple journals, to ‘salami-slicing,’ 
where authors add small amounts of new data to a 
previous paper. Plagiarism can be said to have clearly 
occurred when large chunks of text have been cut-and-
pasted. Such manuscripts would not be considered 
for publication in CTS. But minor plagiarism without 
dishonest intent is relatively frequent, for example, 
when an author reuses parts of an introduction from 
an earlier paper. The journal editors judge any case 
of which they become aware (either by their own 
knowledge of and reading about the literature, or 
when alerted by referees) on its own merits. If a case 
of plagiarism comes to light after a paper is published, 
the journal will conduct a preliminary investigation. If 
plagiarism is found, the journal will contact the author’s 
institute and funding agencies. A determination of 
misconduct will lead the journal to run a statement, 
bidirectionally linked online to and from the original 
paper, to note the plagiarism and to provide a reference 
to the plagiarized material. The paper containing the 
plagiarism will also be obviously marked on each page 
of the PDF. Depending on the extent of the plagiarism, 
the paper may also be formally retracted.
IMAGE INTEGRITY AND STANDARDS 
Images submitted with a manuscript for review should 
be minimally processed (for instance, to add arrows to 
a micrograph). Authors should retain their unprocessed 
data and metadata files, as editors may request them 
to aid in manuscript evaluation. If unprocessed data 
are unavailable, manuscript evaluation may be stalled 
until the issue is resolved. A certain degree of image 
processing is acceptable for publication (and for some 
experiments, fields and techniques is unavoidable), but 
the final image must correctly represent the original 
data and conform to community standards. The 
guidelines below will aid in accurate data presentation 
at the image processing level; authors must also take 
care to exercise prudence during data acquisition, 
where misrepresentation must equally be avoided. 
Authors should list all image acquisition tools and image 
processing software packages used. Authors should 
document key image gathering settings and processing 
manipulations in the Methods. Images gathered at 
different times or from different locations should not be 
combined into a single image, unless it is stated that the 
resultant image is a product of time-averaged data or a 
time-lapse sequence. If juxtaposing images is essential, 
the borders should be clearly demarcated in the figure 
and described in the legend. The use of touch-up tools, 
such as cloning and healing tools in Photoshop, or any 
feature that deliberately obscures manipulations, is to 
be avoided. Processing (such as changing brightness 
and contrast) is appropriate only when it is applied 
equally across the entire image and is applied equally to 
controls. Contrast should not be adjusted so that data 
disappear. Excessive manipulations, such as processing 
to emphasize one region in the image at the expense 
of others (for example, through the use of a biased 
choice of threshold settings), is inappropriate, as is 
emphasizing experimental data relative to the control. 
When submitting revised final figures, authors may be 
asked to submit original, unprocessed images.
CONFIDENTIALITY  
CTS editors and editorial staff keep confidential 
all details about a submitted manuscript and do 
not comment to any outside organization about 
manuscripts under consideration by the journal 
while they are under consideration or if they are 
rejected. The journal editors may comment publicly on 
published material, but their comments are restricted 
to the content itself. After a manuscript is submitted, 
correspondence with the journal, referees’ reports 
and other confidential material, whether or not the 
submission is eventually published, must not be posted 
on any website or otherwise publicized without prior 
permission from the editors. The editors themselves are 
not allowed to discuss manuscripts with third parties or 
to reveal information about correspondence and other 
interactions with authors and referees. Referees agree 
to maintain confidentiality of all manuscripts under 
consideration.
COMMUNICATION WITH THE MEDIA  
Authors must not discuss contributions with the 
media (including other scientific journals) until the 
publication date. The only exception is in the week 
before publication, during which contributions may 
be discussed with the media if authors and their 
representatives (institutions, funders) clearly indicate 
to journalists that their contents must not be publicized 
until the journal’s press embargo has elapsed. Authors 
will be informed of embargo dates and timings after 
acceptance for publication of their articles. We reserve 
the right to halt the consideration or publication 
of a paper if this condition is broken. From time to 
time CTS will distribute to a registered list a press 
release summarizing selected content. Journalists 
are encouraged to read the full version of any 
papers they wish to cover, and are given the names 
of corresponding authors, together with phone 
and fax numbers and email addresses. They receive 
access to the full text of papers about a week before 
publication on a password-protected website. The 
content of the press release and papers is embargoed 
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until the time and date clearly stated on the press 
release. Authors may therefore receive calls or emails 
from the media during this time; we encourage them 
to cooperate with journalists so that media coverage 
of their work is accurate and balanced. Authors may 
also arrange their own publicity (for instance through 
their institutional press offices), but they must 
strictly adhere to our press embargo. 
COMMUNICATION BETWEEN SCIENTISTS  
CTS does not wish to hinder communication between 
scientists. For that reason, different embargo guidelines 
apply to work that has been discussed at a conference 
or displayed on a preprint server and picked up by the 
media as a result. (Neither conference presentations 
nor posting on recognized preprint servers constitute 
prior publication.)
CORRECTION AND RETRACTION POLICY 
We recognize our responsibility to correct errors that 
we have previously published. Our policy is to consider 
refutations (readers’ criticisms) of primary research 
papers, and to publish them online (in concise form) 
if and only if the author provides compelling evidence 
that a major claim of the original paper was incorrect. 
Corrections are published for significant errors at the 
discretion of the editors. Readers who have identified 
such an error should send an email to the editorial 
office of the journal, clearly stating the publication 
reference, title, author, and section of the article, and 
briefly explaining the error.
CORRECTIONS TO THE PRINT AND ONLINE VERSIONS 
OF PEER-REVIEWED CONTENT 
Publishable amendments requested by the authors of 
the publication are represented by an online notice in 
the journal because they affect the publication record 
and/or the scientific accuracy of published information. 
Where these amendments concern peer-reviewed 
material, they fall into one of four categories: erratum, 
corrigendum, retraction, or addendum, described here.
Erratum Notification of an important error made by 
the journal that affects the publication record or the 
scientific integrity of the paper, or the reputation of the 
authors or the journal.
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